亚马逊迷幻之旅：心灵治愈还是健康隐患？
In the sticky heat of Iquitos, the unlikely gateway to the Peruvian Amazon, a new kind of traveller queues outside makeshift clinics and jungle lodges. They are not malariologists or birdwatchers, but software engineers, retired bankers, and grief-stricken parents clutching referrals from underground psychedelic networks. Lured by anecdotal reports of ayahuasca’s power to dissolve depression, post-traumatic stress, and even addiction, thousands of foreigners now stream into the region each year, sustaining a sprawling and largely unregulated industry of retreats that promise profound emotional rebirth. Yet behind the carefully curated Instagram testimonials, a more troubling clinical reality is emerging: a small but worrying number of participants end up in emergency wards with acute psychosis, serotonin syndrome, or severe dissociative episodes that outlast the ceremonially induced visions.
Proponents argue that the liana-based brew, traditionally used by Shipibo, Asháninka, and other Indigenous groups, offers a pharmacologically plausible route to neuroplasticity through its active compound N,N-Dimethyltryptamine (DMT) and its monoamine oxidase inhibitors. The hype is not entirely unfounded: neuroimaging studies on advanced meditators and early clinical trials with psilocybin suggest that these serotonin 2A receptor agonists can temporarily remodel rigid neural pathways associated with rumination and addictive behaviours. However, the retreat model frequently dispenses with the careful patient screening, medical monitoring, and psychological integration that characterize evidence-based psychedelic therapy. An individual with latent bipolar disorder, for instance, can experience a florid manic episode triggered by the intense oneirogenic state—a risk that most jungle facilitators, however well-intentioned, are ill-equipped to manage.
Vocabsavvy AI · a public-health writer · Vocabsavvy Original